Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
Authors:
- Ulrich MrowietzUMUlrich Mrowietz
- Rachel SommerRSRachel Sommer
- Ziad ReguiaiZRZiad Reguiai
- Sascha GerdesSGSascha Gerdes
- Esteban DaudénEDEsteban Daudén
- Wolfgang WegerWWWolfgang Weger
- Julia-Tatjana MaulJMJulia-Tatjana Maul
- Luigi NaldiLNLuigi Naldi
- Pierre-Dominique GhislainPGPierre-Dominique Ghislain
- Philip LawsPLPhilip Laws
- Elke Mgj De JongEJElke Mgj De Jong
- Sicily MburuSMSicily Mburu
Open Access
- 1 May 2026
- journal article
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-11
Abstract
Psoriasis extends beyond skin manifestations and significantly impacts patients’ psychological health, social interactions, and daily functioning. The main objective was to assess the 2-year effect of tildrakizumab, an interleukin-23p19 inhibitor, on the skin, the psychological well-being and the health-related quality of life (HRQoL) of people with psoriatic disease in real-world. The POSITIVE study is a 24-month, prospective observational multinational study enrolling adults with moderate-to-severe plaque psoriasis treated with tildrakizumab according to clinical practice. Outcome measurements included the 5-item WHO Well-being Index (WHO-5), Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index-Relevant (DLQI-R). 785 patients were included. The mean (95% CI) WHO-5 score increased from 53.7 (52.2, 55.3) at baseline to 63.2 (61.5, 64.8) at W16 and continued improving over time: 65.9 (64.0, 67.9) at W52 and 70.4 (68.1, 72.7) at W104. The mean (95% CI) PASI decreased from 12.9 (12.3, 13.5) at baseline to 2.4 (2.2, 2.7) at W16 and was maintained until W104 [1.3 (1.1, 1.5)]. At W104, 87.9/79.0/65.1% of patients maintained PASI ≤3/≤2/≤1. Drug survival due to lack of effectiveness or adverse events (AE) was 87.8% and 96.3% after 2 years. The mean (95% CI) DLQI-R score decreased from 12.0 (11.4, 12.6) at baseline to 3.1 (2.6, 3.6) W52 and 2.1 (1.7, 2.5) at W104. At the final analysis, 11.1% of patients had ≥1 related AE. Treatment with tildrakizumab delivered sustained and holistic long-term health for moderate to severe psoriasis over 2 years by consistently improving patients’ psychological well-being, life and clinical outcomes with a favourable safety profile. NCT04823247Keywords
This publication has 35 references indexed in Scilit:
- Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease AreasAdvances in Therapy, 2025
- Burden to Partners of People with Psoriasis: Results from the FamilyPso International StudyAmerican Journal of Clinical Dermatology, 2025
- Global burden of psoriasis from 1990 to 2021: A population-based analysisJournal of the American Academy of Dermatology, 2025
- Patient's Perspective on the Impact of Psoriasis on Their Quality of Life After 1 Year of Tildrakizumab Treatment: Despite Clinical Improvement, Persistence of a Potential Mental Cicatricial Memory of the DiseaseJEADV Clinical Practice, 2025
- A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical PracticeDermatology and Therapy, 2024
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Psoriasis and suicidality: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2017
- Correlates of diabetes-related distress in type 2 diabetes: Findings from the benchmarking network for clinical and humanistic outcomes in diabetes (BENCH-D) studyJournal of Psychosomatic Research, 2015
- The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseasesArchives of Dermatological Research, 2009
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004